Japan Tobacco

cigarette manufacturing company

Elvitegravir (EVG) is an integrase inhibitor used to treat HIV infection. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by the U.S. Food and Drug Administration on 27 August 2012, for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild. On 24 September 2014, the FDA approved Elvitegravir as a single pill formulation under the trade name Vitekta. On 5 November 2015, the FDA approved the drug for use in patients affected with HIV-1 as

company

Japanese women's volleyball team

former international tobacco and cigarette company

chemical compound

Russian cigarette and tobacco company

Japanese volleyball club

Museum in Tokyo, Japan

JTE-907 is a drug used in scientific research that acts as a selective CB2 inverse agonist. It has anti-inflammatory effects in animal studies, thought to be mediated by an interaction between the CB2 receptor and IgE.